$14.78 0.7%
TXG Stock Price vs. AI Score
Data gathered: December 26

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - 10X Genomics (TXG)

Analysis generated October 11, 2024. Powered by Chat GPT.

10X Genomics is a biotechnology company that specializes in advanced genomics research technologies and products. Their innovative solutions are utilized widely within the scientific and medical communities for single-cell analysis, spatial gene expression, and immune profiling, thereby facilitating breakthroughs in research and diagnostics. The company’s technology is at the forefront of genomics, pushing the boundaries of possibilities in understanding concerning complex diseases and biological mysteries.

Read full AI stock Analysis

Stock Alerts - 10X Genomics (TXG)

company logo 10X Genomics | December 23
Price is up by 5.3% in the last 24h.
company logo 10X Genomics | December 20
Price is up by 5.4% in the last 24h.
company logo 10X Genomics | December 18
Price is down by -5.4% in the last 24h.
company logo 10X Genomics | December 16
Price is up by 5.6% in the last 24h.

About 10X Genomics

A life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific.


10X Genomics
Price $14.78
Target Price Sign up
Volume 161,820
Market Cap $1.78B
Year Range $13.18 - $29.28
Dividend Yield 0%
Analyst Rating 55% buy
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24152M45M106M-36M-40M-0.300
Q2 '24153M49M104M-38M-40M-0.320
Q1 '24141M48M93M-60M-56M-0.500
Q4 '23184M68M116M-49M-45M-0.410
Q3 '23154M58M96M-93M-90M-0.790

Insider Transactions View All

Hindson Benjamin J. filed to sell 339,897 shares at $13.7.
November 25 '24
Saxonov Serge filed to sell 872,574 shares at $13.7.
November 25 '24
McAnear Justin J. filed to sell 143,242 shares at $22.5.
August 26 '24
Hindson Benjamin J. filed to sell 345,704 shares at $22.5.
August 26 '24
Saxonov Serge filed to sell 882,467 shares at $22.5.
August 26 '24

What is the Market Cap of 10X Genomics?

The Market Cap of 10X Genomics is $1.78B.

What is the current stock price of 10X Genomics?

Currently, the price of one share of 10X Genomics stock is $14.78.

How can I analyze the TXG stock price chart for investment decisions?

The TXG stock price chart above provides a comprehensive visual representation of 10X Genomics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling 10X Genomics shares. Our platform offers an up-to-date TXG stock price chart, along with technical data analysis and alternative data insights.

Does TXG offer dividends to its shareholders?

As of our latest update, 10X Genomics (TXG) does not offer dividends to its shareholders. Investors interested in 10X Genomics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of 10X Genomics?

Some of the similar stocks of 10X Genomics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.